Background
This case arose from an interference proceeding — a USPTO contest to determine which of two competing patent applicants was first to invent a common subject matter. At stake were patents covering insulin-like growth factor I (IGF-I), a recombinant protein with therapeutic potential. Genentech’s Lee application and Chiron’s Rinderknecht application both claimed priority to IGF-I inventions made using recombinant DNA technology.
Genentech argued that its inventors had reduced IGF-I to practice before Chiron’s effective filing date. The key evidence was that Genentech’s scientists had produced a protein, and a Genentech collaborator — a third party, not one of the named inventors — had recognized that the protein was biologically active and useful. The Board of Patent Appeals and Interferences awarded priority to Genentech. Chiron appealed.
The Court’s Holding
The Federal Circuit reversed. Writing for the court, Judge Lourie held that actual reduction to practice of a chemical or biological compound requires the inventors themselves to recognize the utility of what they have made — not a third party collaborator. The recognition of utility is an essential component of reduction to practice, not merely confirmation of something already achieved.
Where a non-inventor is the first to recognize that a compound or protein works for its intended purpose, the inventors cannot claim credit for having reduced the invention to practice as of that recognition date. Only when the inventors (or someone acting under their direction and for their benefit) understand that the produced material has the claimed utility does actual reduction to practice occur. Because the third party’s recognition of IGF-I’s utility could not be attributed to the inventors, Genentech failed to establish reduction to practice before Chiron’s filing date.
The decision underscored the importance of contemporaneous documentation in pharmaceutical and biotechnology patent interference proceedings: inventors must not only produce the claimed compound, but must themselves appreciate what they have made and record that appreciation to establish a priority date.
Key Takeaways
- Actual reduction to practice of a chemical or biological invention requires the inventors — not a third party — to recognize the utility of the claimed compound or composition.
- A non-inventor collaborator’s recognition of utility cannot be attributed to the inventors for purposes of establishing a reduction-to-practice date.
- Contemporaneous lab notebooks, test records, and inventor statements about a compound’s activity are critical in interference and priority disputes to prove that inventors appreciated the utility of their work at a specific time.
- In recombinant protein disputes, producing the protein is not enough — inventors must also demonstrate that they understood the protein’s therapeutic or functional significance within the priority period.
- This decision shaped how biotechnology patent applicants document inventor understanding during early-stage protein research.
Why It Matters
Genentech v. Chiron illuminates a subtle but critical requirement in biotechnology patent law: it is not enough to make a compound — inventors must know what they have made and appreciate its significance. In recombinant protein research, it is common for scientists to produce novel proteins and then send them to collaborators or contract laboratories for biological testing. If the collaborator is the first to recognize the protein’s utility, the inventors may have lost their priority date.
For biotech companies, the practical message is clear: document everything, and document it in a way that shows inventor understanding, not just production. A laboratory notebook entry showing that an ingredient was synthesized means less than one showing that the inventors tested it, observed biological activity, and understood what that meant. As the biotech industry continued to mature in the 2000s, this decision reinforced rigorous documentation practices that remain important in any setting where inventorship and utility recognition could be disputed.